Laboratory Medicine ›› 2019, Vol. 34 ›› Issue (9): 841-843.DOI: 10.3969/j.issn.1673-8640.2019.09.016
Previous Articles Next Articles
Received:2018-07-04
Online:2019-09-30
Published:2019-09-29
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2019.09.016
| 组别 | 例数 | ACTIN | FSL | SynthAsil |
|---|---|---|---|---|
| 观察组 | 63 | 39.62±12.57 | 39.24±12.04 | 49.22±18.92 |
| 对照组 | 58 | 30.20±5.10 | 30.05±3.02 | 33.29±4.28 |
| t值 | 24.81 | 25.66 | 20.48 | |
| P值 | 0.000 | 0.000 | 0.000 |
| 组别 | 例数 | ACTIN | FSL | SynthAsil |
|---|---|---|---|---|
| 观察组 | 63 | 39.62±12.57 | 39.24±12.04 | 49.22±18.92 |
| 对照组 | 58 | 30.20±5.10 | 30.05±3.02 | 33.29±4.28 |
| t值 | 24.81 | 25.66 | 20.48 | |
| P值 | 0.000 | 0.000 | 0.000 |
| 试剂 | 曲线下面积 | 标准误 | 95%可信区间 | P值 |
|---|---|---|---|---|
| ACTIN | 0.726 | 0.050 | 0.629~0.824 | <0.000 1 |
| FSL | 0.777 | 0.046 | 0.687~0.866 | <0.000 1 |
| SynthAsil | 0.800 | 0.044 | 0.714~0.885 | <0.000 1 |
| 试剂 | 曲线下面积 | 标准误 | 95%可信区间 | P值 |
|---|---|---|---|---|
| ACTIN | 0.726 | 0.050 | 0.629~0.824 | <0.000 1 |
| FSL | 0.777 | 0.046 | 0.687~0.866 | <0.000 1 |
| SynthAsil | 0.800 | 0.044 | 0.714~0.885 | <0.000 1 |
| 试剂 | 最佳临界值 | 敏感性 | 特异性 | 约登指数 |
|---|---|---|---|---|
| ACTIN | 38.2 | 0.468 | 0.944 | 0.412 |
| FSL | 32.9 | 0.613 | 0.833 | 0.446 |
| SynthAsil | 38.5 | 0.581 | 0.917 | 0.498 |
| 试剂 | 最佳临界值 | 敏感性 | 特异性 | 约登指数 |
|---|---|---|---|---|
| ACTIN | 38.2 | 0.468 | 0.944 | 0.412 |
| FSL | 32.9 | 0.613 | 0.833 | 0.446 |
| SynthAsil | 38.5 | 0.581 | 0.917 | 0.498 |
| [1] | 中华医学会风湿病学分会. 抗磷脂综合征诊断和治疗指南[J]. 中华风湿病学杂志,2011,15(6): 407-410. |
| [2] | SAHEBARI M,RASTIN M,BOOSTANI R,et al.Subtypes of antiphospholipid antibodies in neurologic disorders:an observational study[J]. Curr Rheumatol Rev,2019,15(1):59-66. |
| [3] | GABBAY-BENZIV R,ZAFRIR-DANIELI H,BLICKSTEIN D,et al.Antiphospholipid syndrome characteristics and adverse pregnancy outcomes after 20 weeks of pregnancy[J]. Int J Gynaecol Obstet,2018,142(2):214-220. |
| [4] | LES I,PARRAZA N,ANAUT P,et al.Length of exposure to antiphospholipid antibodies,rather than age,is a risk factor for thrombosis:a retrospective single-centre observational study[J]. Rheumatol Int,2018,38(2):229-238. |
| [5] | PYO J Y,JUNG S M,LEE S W,et al.Subsequent thrombotic outcomes in patients with ischemic stroke with antiphospholipid antibody positivity[J]. Yonsei Med J,2017,58(6):1128-1134. |
| [6] | NAVARRO-CARPENTIERI D,DEL CARMEN CASTILLO-HERNANDEZ M,MAJLUF-CRUZ K,et al. Impact of classical risk factors for arterial or venous thrombosis in patients with antiphospholipid syndrome[J]. Clin Appl Thromb Hemost,2018,24(5):834-840. |
| [7] | FAVALORO E J,BONAR R,MARSDEN K.Internal quality control and external quality assurance in testing for antiphospholipid antibodies:Part Ⅱ-lupus anticoagulant[J]. Semin Thromb Hemost,2012,38(4):404-411. |
| [8] | TRIPODI A.Laboratory testing for lupus anticoagulants: a review of issues affecting results[J]. Clin Chem,2007,53(9) :1629-1635. |
| [9] | 寿玮龄,陈倩,吴卫,等. 不同狼疮抗凝物检测试验的临床诊断效能研究[J]. 中华医学杂志,2015,95(34):2760-2765. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
